Drug Trial Radar · NCT07181187
Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Mar 26, 2024
Primary completion
Sep 24, 2025
Study completion May 7, 2026
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with vitiligo.
Conditions
- Vitiligo
Interventions
MH004 OintmentDrug
MH004 1% ointment applied topically to the affected area as a thin film once or twice daily.
Vehicle OintmentDrug
Matching vehicle ointment applied topically to the affected area as a thin film once or twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Facial Vitiligo Area Scoring Index 50(F-VASI50) at Week 24.Time frame: Baseline; Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.